DexCom, Inc. (DXCM) earnings
DXCM earnings moved a median of +0.82% by the close. Quarterly and annual DXCM reports and results, each read against the price at its own news timestamp. Back to the DXCM overview →
22 measured DXCM earnings events.
Where these DXCM earnings landedvs 22 measured DXCM earnings reactions
| Middle 50% of DXCM earnings reactions | -0.44% to +1.32% |
|---|---|
| Median reaction (to close) | +0.82% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 DXCM earnings events with a measured close landed between -0.44% and +1.32%; 73% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time | Press release | +1.50% | +0.51% | |
| Dexcom Reports Second Quarter 2026 Financial Results | Press release | +2.21% | +4.31% | |
| Form 10-Q DEXCOM INC For: Jun 30 | SEC filing · Form 10-Q | +2.21% | +4.31% | |
| Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time | Press release | -0.95% | -0.72% | |
| Dexcom Reports First Quarter 2026 Financial Results | Press release | +1.69% | +1.32% | |
| Form 10-Q DEXCOM INC For: Mar 31 | SEC filing · Form 10-Q | +1.69% | +1.32% | |
| Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time | Press release | -1.32% | +1.17% | |
| Form 10-K DEXCOM INC For: Dec 31 | SEC filing · Form 10-K | +5.45% | +7.72% | |
| Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time. | Press release | -0.47% | +1.04% | |
| Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance | Press release | +0.54% | -2.35% | |
| Form 10-Q DEXCOM INC For: Sep 30 | SEC filing · Form 10-Q | +0.54% | -2.35% | |
| Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time. | Press release | -0.34% | +1.05% | |
| Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan | Press release | -2.87% | -5.75% | |
| Form 10-Q DEXCOM INC For: Jun 30 | SEC filing · Form 10-Q | -2.87% | -5.75% | |
| Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. | Press release | +1.45% | +0.38% | |
| Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program | Press release | +2.38% | +8.26% | |
| Form 10-Q DEXCOM INC For: Mar 31 | SEC filing · Form 10-Q | +2.38% | +8.26% | |
| Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time. | Press release | -0.46% | -4.76% | |
| Form 10-K DEXCOM INC For: Dec 31 | SEC filing · Form 10-K | +1.12% | +0.59% | |
| Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time. | Press release | +1.54% | +1.17% | |
| Dexcom Reports Third Quarter 2024 Financial Results | Press release | +0.28% | +0.60% | |
| Form 10-Q DEXCOM INC For: Sep 30 | SEC filing · Form 10-Q | +0.28% | +0.60% |
Keep exploring
More DXCM: analyst actions → · SEC filings → · DXCM overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AETNA (AET) | 2,000+ | +0.06% | 58% |
| ALLERGAN INC (AGN) | 2,000+ | +0.04% | 54% |
| Endo International plc - Ordinary Shares (ENDP) | 2,000+ | 0.00% | 49% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2,000+ | +0.11% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.